MA-CENTERITY
22.10.2020 15:02:08 CEST | Business Wire | Press release
Centerity Systems, Inc. , the leading AIOps Platform with advanced performance analytics and integrated security, today announced its recognition as a Top Value Leader in the latest “EMA Radar Report: AIOps – A Guide for Investing in Innovation .”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022005664/en/
EMA evaluated 17 AIOps vendors on (i) Business Impact and IT-to-Business Alignment, (ii) Incident, Performance, and Availability Management, and (iii) Change Impact and Capacity Optimization use cases to guide organizations with their AIOps platform selection. Centerity’s AIOps Platform is designated as a market leader in all of the use cases EMA evaluated. Centerity is a front-runner in delivering exceptional value in both the Business Impact and IT-to-Business Alignment and Incident, Performance, and Availability Management use cases, due to its technical strength, impact on business outcomes, and deployment cost efficiency. In addition, Centerity was honored by EMA with a special award for advanced integrated security functionality.
The Centerity AIOps Platform improves performance and reliability of business and operational processes, employing an approach that continuously measures the overall health of key technology services by providing real-time, consolidated business analytics. SLA executive dashboards expose business and security risks, identify performance anomalies, and provide fault isolation across applications, operating systems, infrastructure and cloud assets. It does this by automating topology and dependency maps of all IT assets, incorporating each asset into business and operational service views. Its AI-driven anomaly detection and multi-tenancy supports multi-user, multi-vendor, and multi-location management, which is ideal for managed service providers, cloud service providers, and enterprises.
“Centerity is a unique innovator in the AIOps arena,” said Dennis Drogseth, EMA vice president. “Centerity stands out for its advancing use of AI/ML in a variety of contexts, including ‘CyberOps,’ as well as its distinctive strengths in discovery across domains, data assimilation, and unifying views and dashboards. These strengths, along with the platform’s fast time to value and limited administrative overhead all help to make Centerity both a versatile and progressive choice for AIOps adopters.” According to EMA’s evaluation, the Centerity AIOps platform is differentiated among its competitors by:
-
Delivering many of the benefits of larger and more costly AIOps suites with reduced administrative overhead and more modest software costs.
-
Bringing the full seven-layer stack together with an eye toward IT service performance and business outcomes and priorities across cloud, hybrid, and legacy environments.
- Integrating artificial intelligence and machine learning capabilities to support security and risk management needs – such as cybersecurity compliance, endpoint detection and response (EDR), supply chain security, and automated prevention of attacks on network hardware.
According to EMA, the message for IT organizations looking to pursue a forward path in AIOps adoption is overall a strongly positive one. The benefits achieved are growing in diversity and value. AIOps can and should be transformative in enabling more effective decision-making, data sharing, and analytics-driven automation. The recommendation from EMA remains that buyers should consider their own realities, then begin a search for the AIOps platform that most fits their requirements.
“In the digital age, AIOps, security and risk management must be observed and correlated through a single platform,” said Roi Keren, CEO of Centerity Systems. “That’s not only what we see our customers need and want, it’s what Centerity does best. EMA’s positioning of Centerity and award for integrated security acknowledges the convergence of AIOps and security. It’s more critical than ever for enterprise executives – whether you’re a CIO, CISO, CEO, or board member -- to make strategic, risk-based business decisions with one platform, one dashboard; in essence, a single source of truth.”
AIOps Deployments and the Real Word: Bringing Operations and Security Together
Enterprises can see how others are deploying AIOps to address a variety of use cases by viewing a live EMA-hosted webcast titled “AIOps Deployments and the Real World: Bringing Operations and Security Together ,” which will be held on Tuesday, November 10th at 1:00 pm EST. You can register for the webcast at https://info.enterprisemanagement.com/aiops-deployments-in-the-real-world-webinar-centerity .
About Centerity
Centerity’s Cyber-AIOps Platform with advanced Integrated Security delivers Dynamic Business Service Views of the full technology stack to the executives responsible for technology-driven business services, ensuring the performance, availability and security of critical processes. Centerity displays real-time, consolidated business analytics for complex on-prem, cloud, and hybrid technology environments generating SLA Executive Dashboards that identify performance anomalies and isolate faults across applications, operating systems, infrastructure and cloud assets. Learn more at centerity.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005664/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
